secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-153013
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir approves $100K transaction bonuses for CEO, CFO, GC contingent on 2024 change of control
--------------------------------------------------------------------------------

- Board approved $100K cash bonuses to CEO Diana Brainard, President/CFO Vikas Sinha, and GC Edward Miller.
- Bonuses contingent on Board execution of a definitive change of control agreement in fiscal 2024 and continued employment through closing.
- Payments are termed Transaction Bonuses; Brainard and Sinha abstained from voting on their own bonuses.
- The bonuses signal active pursuit of a strategic transaction, likely a sale or merger of the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524153013/0001193125-24-153013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524153013/d799803d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-153013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer